Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OraSure OTC HIV Test To Enter Phase II Trials By Summer

This article was originally published in The Tan Sheet

Executive Summary

HIV test kit manufacturer OraSure Technologies should be required to conduct actual-use studies as part of Phase III trial commitments, according to an FDA advisory panel

You may also be interested in...



Chembio HIV Tests Could Present OTC Competition For OraSure

Chembio Diagnostics intends to pursue OTC status for its SURE CHECK HIV 1/2 and HIV 1/2 STAT-PAK rapid tests, the company said upon announcing FDA approval of the two products May 30

Chembio HIV Tests Could Present OTC Competition For OraSure

Chembio Diagnostics intends to pursue OTC status for its SURE CHECK HIV 1/2 and HIV 1/2 STAT-PAK rapid tests, the company said upon announcing FDA approval of the two products May 30

Chembio HIV Tests Could Present OTC Competition For OraSure

Chembio Diagnostics intends to pursue OTC status for its SURE CHECK HIV 1/2 and HIV 1/2 STAT-PAK rapid tests, the company said upon announcing FDA approval of the two products May 30

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel